N-[(5R,8S,10R)-2,6-dimethyl-ergoline-8-yl]-2-ethyl-2-methyl-butanamide | 121879-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[(5R,8S,10R)-2,6-dimethyl-ergoline-8-yl]-2-ethyl-2-methyl-butanamide
• 英文别名: N-((8a)-2,6-Dimethylergolin-8-yl)-2-ethyl-2-methylbutanamide；N-[(6aR,9S,10aR)-5,7-dimethyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-2-ethyl-2-methylbutanamide
• CAS: 121879-58-1
• 化学式: C₂₃H₃₃N₃O
• 分子量: 367.535
• InChiKey: UXRWQKITDPCICD-QKYXUNIQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  48.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙基-2-甲基丁酰氯 、 8α-amino-2,6-dimethyl-ergoline 生成 N-[(5R,8S,10R)-2,6-dimethyl-ergoline-8-yl]-2-ethyl-2-methyl-butanamide
  参考文献：
  名称：

  HAEFLIGER, WALTER

  摘要：

  DOI：

文献信息

• SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20120071493A1

  公开（公告）日：2012-03-22

  The invention relates to novel substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of the general formula 1 and their pharmaceutically acceptable salt—ligands exhibiting biological activity simultaneously towards alpha-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepinefrine receptors, serotonin receptors, to active components, pharmaceutical compositions, comprising as an active component novel ligands, to novel medicaments intended for treatment of conditions and diseases of central nervous system. In the general formula 1 R 1 represents a substituent selected from hydrogen, optionally substituted C 1 -C 3 alkyl or C 1 -C 4 alkyloxycarbonyl; R 2 represents a cyclic system substituent selected from hydrogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 2 -C 3 alkenyl or substituted sulfonyl; R 3 represents optionally substituted aryl or substituted amino group.

  该发明涉及一种新型的取代的8-磺酰基-2,3,4,5-四氢-1H-γ-咔啉的化合物，其一般式为1，以及它们的药用盐——配体，同时对α-肾上腺素受体、多巴胺受体、组胺受体、咪唑啉受体、西格玛受体、去甲肾上腺素受体、5-羟色胺受体表现出生物活性的配体，以及作为活性成分的新型配体组成的药物组合物，用于治疗中枢神经系统疾病和病症的新型药物。在一般式1中，R1代表从氢、可选取代的C1-C3烷基或C1-C4烷氧羰基中选择的取代基；R2代表从氢、可选取代的C1-C3烷基、可选取代的C2-C3烯基或取代的磺酰基中选择的环系统取代基；R3代表可选取代的芳基或取代的氨基团。
• 8.alpha.-acylaminoergoline, its preparation and pharmaceutical
  申请人：Sandoz Ltd.

  公开号：US05075318A1

  公开（公告）日：1991-12-24

  8.alpha.-Acylaminoergoline useful in the treatment of psychotic disorders and Parkinson's disease.

  8.alpha.-酰胺基麦角碱可用于治疗精神疾病和帕金森病。
• JP1022876A
  申请人：——

  公开号：JP1022876A

  公开（公告）日：1989-01-25
• LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110039825A1

  公开（公告）日：2011-02-17

  The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT 7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C 1 -C 4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C 1 -C 4 alkyl, CF 3 , CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH 2 ) m group, optionally substituted CH═CH group, optionally substituted CH 2 —CH═CH group, C≡C group, SO 2 group; n=1, 2; m=1, 2, 3; solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.
• LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT
  申请人：Ivaschenko Andrey Alexandrovich

  公开号：US20110136853A1

  公开（公告）日：2011-06-09

  The present invention is directed to the novel ligand with wide range of pharmacological activity including activity to GPCR receptors, ion channels and monoamine transporters representing 3-methyl-9-benzyl-1,2,3,4-tetrahydrocarboline naphthalene-1,5-disulfonate of formula 1 The invention is also directed to the novel drug substance, Pharmaceutical formulation comprising the novel drug substance, and to the method for its preparation, to the novel medicaments, and method for treatment of CNS diseases including neurodegenerative diseases and cognitive disorders at humans and warm blooded animals.